Related Experiment Video
Updated: Sep 13, 2025

Full-root Aortic Valve Replacement by Stentless Aortic Xenografts in Patients with Small Aortic Roots
Published on: May 21, 2017
Platelet Count Drop After Aortic Valve Bioprostheses Implantation: Short and Long-Term Outcomes
Anna Olasińska-Wiśniewska1, Bartłomiej Perek1, Michał Bociański1
1Department of Cardiac Surgery and Transplantology, Poznan University of Medical Sciences, Poznan, Poland.
Background:
Surgical aortic valve replacement (SAVR) and transcatheter aortic valve implantation (TAVI) have evolved significantly in recent years. Postoperative thrombocytopenia has been observed after both techniques. The study aimed to assess if postprocedural platelet count drop (PCD) influenced early results and 1-year survival in patients treated with SAVR and TAVI. The secondary aim was to compare the degrees of PCD between techniques.
Method:
The retrospective single-centre study involved patients treated for symptomatic aortic stenosis. Periprocedural platelet count characteristic was evaluated. One-year mortality was assessed.
Results:
The study group consisted of 313 patients, including the Perceval group (n=73), the Resilia group (n=17), the TAVI group treated between 2013 and 2017 (n=140), and with newer bioprostheses implanted between May 2021 and July 2022 (n=83). Baseline platelet count did not differ between groups (p=0.116). All patients, apart from two (both in the TAVI groups), presented with any postprocedural PCD. The most prominent PCD in all groups was observed on the second and third postoperative days but was the most pronounced in the Perceval prosthesis group (p<0.001), with PCD >50% in 66 patients (90.4%). Twenty-two (22) patients died during the first postoperative year, five in the new TAVI, 12 in the early TAVI, and five in the Perceval groups. Patients who died did not differ significantly in PCD value compared with 1-year survivors in all study groups. A probability of 1-year survival according to the Kaplan-Meier curve was comparable between the studied groups (p=0.793). Early TAVI patients with PCD >50% were burdened with a higher risk of complications, including bleeding complications (p=0.032), blood transfusion (p=0.04), and acute kidney injury (p=0.005).
Conclusions:
Thrombocytopenia is a common phenomenon in patients treated with TAVI and SAVR but has no impact on 1-year survival. The implantation of newer models of bioprostheses, both transcatheter and surgical, is associated with a smaller decrease in platelet counts.
More Related Videos
14:14Standardized Technique of Aortic Valve Re-implantation for Valve-sparing Aortic Root Replacement
Published on: December 11, 2017
05:31Transcatheter Pulmonary Valve Replacement from Autologous Pericardium with a Self-Expandable Nitinol Stent in an Adult Sheep Model
Published on: June 8, 2022
Related Concept Videos
Aortic Regurgitation I: Introduction
Aortic Regurgitation II: Clinical Features and Diagnostic Tests
Aortic Regurgitation III: Medical Management
Aneurysm III: Interprofessional Care
Formation of the Platelet Plug
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...